Affiliation:
1. Chongqing Key Laboratory of Natural Product Synthesis and Drug Research School of Pharmaceutical Sciences Chongqing University No. 55 Daxuecheng South Road, Shapingba Chongqing 401331 P. R. China
2. Chongqing Energy College No. 2 Fuxing Avenue, Shuangfu New District, Jiangjin District Chongqing 402260 P. R. China
3. College of Pharmacy Chongqing Medical University Yixueyuan Road, Yuzhong District Chongqing 400016 P. R. China
Abstract
AbstractHonokiol (HK) is a traditional Chinese herbal bioactive compound that originates mainly from the Magnolia species, traditionally used to treat anxiety and stroke, as well as alleviation of flu symptoms. This natural product and its derivatives displayed diverse biological activities, including anticancer, antioxidant, anti‐inflammatory, neuroprotective, and antimicrobial activities. However, its poor bioavailability and pharmacological activity require primary consideration in the development of HK‐based drugs. Recent innovative HK formulations based on the nanotechnology approach allowed for improvement in both bioavailability and therapeutic efficacy. Chemical derivation and drug combination are also effective strategies to ameliorate the drawbacks of HK. In recent years, studies on HK derivatives and compositions have made great progress in the treatment of cancer, inflammation, bacterial infection, cardiovascular, and cerebrovascular diseases, demonstrating better activity than HK. The objective of this review is an examination of the recent developments in the field of pharmacological activity of HK and its drug‐related issues, and approaches to improve its physicochemical and biological properties, including solubility, stability, and bioavailability. Recent patents and the ongoing clinical trials in HK are also summarized.
Funder
National Natural Science Foundation of China
Fundamental Research Funds for the Central Universities
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献